Any thoughts on XPO1 inhibitors, specifically KPTI, whom are conducting a 230-patient trial right now for COVID-19. I know the side effects can be horrible, which led to a failed Adcom last year (only to have the FDA overrule the panel and approved anyway a few months later). KPTI claim the COVID-19 trial is low dosage and taken by pill every two days.
Silviu always said that Vaccines and Antivirals shall have an important future role in helping people with this life-threatening viral infection. Whatever treatments are offered, some people shall fail them as you said, and we can come in as a salvage therapy once the patient has ARDS or about to enter ARDS.
I completely agree that MESO is flying under the radar of the American press, but is one of the leaders in the race for an effective and approved FDA therapeutic.
MSB Price at posting:
$3.69 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)